Geron Corp (NASDAQ:GERN)
| Market Cap | $560.94M-24.9% |
| Revenue (ttm) | $217.52M+18.6% |
| Net Income | -$50.12M+37.3% |
| EPS | -$0.07+42.3% |
| Shares Out | 644.24M |
| PE Ratio | n/a |
| Forward PE | 10.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,832,347 |
| Open | $0.89 |
| Previous Close | $0.91 |
| Day's Range | $0.86 - $0.93 |
| 52-Week Range | $0.84 - $2.01 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | $5.89(+576.47%) |
| Earnings Date | Feb 24, 2027 |
About GERN
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Geron Corp Stock Analysis — InsiderScore
Geron Corp scored higher than 83% of companies evaluated by InsiderBuying, and ranked 16th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Geron Corp bought $62.1K of stock across 2 purchases in the last 90 days, the largest of them $50.8K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
2 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating GERN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$GERN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GERN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GERN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GERN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GERN Revenue by Segment
| Product revenue, net | $60.11M | 91.10% |
| Income (loss) from operations | $5.80M | 8.79% |
| Royalties | $76.00K | 0.12% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GERN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GERN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GERN
| XBIState Street SPDR S&P Biotech ETF | $16.90M |
| VTIVanguard Morningstar Total Stock Market ETF | $14.38M |
| IWMiShares Russell 2000 ETF | $12.80M |
| VXFVanguard Extended Market ETF | $5.94M |
| IWOiShares Russell 2000 Growth ETF | $4.85M |
| IBBiShares Biotechnology ETF | $4.29M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from GERN’s recent data — informational, not investment advice
What’s Behind the Score
News check: RYTELO sales growth and Germany expansion represent positive concrete business developments, offset by stock price decline and investor disappointment.
Recent Insider Activity
Insider Score Trend Over Time
-3.8 since Nov 17Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBP | Virtus Biotech ETF | 1.14% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.42% |
| WDNA | WisdomTree BioRevolution Fund | 0.40% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.39% |
| XBI | State Street SPDR S&P Biotech ETF | 0.18% |
| ESSC | Eventide Small Cap ETF | 0.10% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.07% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.04% |
| IBB | iShares Biotechnology ETF | 0.04% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.04% |
| IWO | iShares Russell 2000 Growth ETF | 0.04% |
| PWS | Pacer WealthShield ETF | 0.04% |
Weight is the stock’s share of each fund’s holdings.
